Literature DB >> 12153989

Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery.

Jayanth Panyam1, Wen-Zhong Zhou, Swayam Prabha, Sanjeeb K Sahoo, Vinod Labhasetwar.   

Abstract

The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation. Current vectors that enable the endo-lysosomal escape of macromolecules such as DNA are limited by their toxicity and by their ability to carry only limited classes of therapeutic agents. In this paper, we report the rapid (<10 min) endo-lysosomal escape of biodegradable nanoparticles (NPs) formulated from the copolymers of poly(DL-lactide-co-glycolide) (PLGA). The mechanism of rapid escape is by selective reversal of the surface charge of NPs (from anionic to cationic) in the acidic endo-lysosomal compartment, which causes the NPs to interact with the endo-lysosomal membrane and escape into the cytosol. PLGA NPs are able to deliver a variety of therapeutic agents, including macromolecules such as DNA and low molecular weight drugs such as dexamethasone, intracellularly at a slow rate, which results in a sustained therapeutic effect. PLGA has a number of advantages over other polymers used in drug and gene delivery including biodegradability, biocompatibility, and approval for human use granted by the U.S. Food and Drug Administration. Hence PLGA is well suited for sustained intracellular delivery of macromolecules.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153989     DOI: 10.1096/fj.02-0088com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  228 in total

1.  Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody.

Authors:  Yoon Ki Joung; Sejin Son; Ji Young Jang; Myung Hee Kwon; Ki Dong Park
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

2.  Quantitative aspects of intracellularly-targeted drug delivery.

Authors:  David Stepensky
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

3.  Intracellular uptake and trafficking of difluoroboron dibenzoylmethane-polylactide nanoparticles in HeLa cells.

Authors:  Janette Contreras; Jiansong Xie; Yin Jie Chen; Hua Pei; Guoqing Zhang; Cassandra L Fraser; Sarah F Hamm-Alvarez
Journal:  ACS Nano       Date:  2010-05-25       Impact factor: 15.881

4.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 5.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

6.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

7.  Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles.

Authors:  Christopher J Scott; Waleed M Marouf; Derek J Quinn; Richard J Buick; Selinda J Orr; Ryan F Donnelly; Paul A McCarron
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

8.  Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy.

Authors:  Sinjan De; Dennis H Robinson
Journal:  AAPS PharmSciTech       Date:  2004-09-13       Impact factor: 3.246

Review 9.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

10.  The uptake and intracellular fate of PLGA nanoparticles in epithelial cells.

Authors:  Malgorzata S Cartiera; Katherine M Johnson; Vanathy Rajendran; Michael J Caplan; W Mark Saltzman
Journal:  Biomaterials       Date:  2009-02-20       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.